Dopaminergic Correlates of Regional Cerebral Blood Flow in Parkinsonian Disorders. 2022

Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.

Cerebral blood flow (CBF) and dopamine transporter (DAT) images are clinically used for the differential diagnosis of parkinsonian disorders. This study aimed to examine the correlation of CBF with striatal DAT in patients with Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) and evaluate the diagnostic power of DAT-correlated CBF in PD through machine learning with each imaging modality alone or in combination. Fifty-eight patients with PD and 71 with APS (24 with multiple system atrophy, 21 with progressive supranuclear palsy, and 26 with corticobasal syndrome) underwent 123 I-IMP and 123 I-FP-CIT single-photon emission computed tomography. Multiple regression analyses for CBF and striatal DAT binding were conducted on each group. PD probability was predicted by machine learning and receiver operating characteristic curves. The PD group showed more affected striatal DAT binding positively correlated with the ipsilateral prefrontal perfusion and negatively with the bilateral cerebellar perfusion. In corticobasal syndrome, striatal DAT binding positively correlated with the ipsilateral prefrontal perfusion and negatively with the contralateral precentral perfusion. In Richardson's syndrome, striatal DAT binding positively correlated with perfusion in the ipsilateral precentral cortex and basal ganglia. Machine learning showed that the combination of CBF and DAT was better for delineating PD from APS (area under the curve [AUC] = 0.87) than either CBF (0.67) or DAT (0.50) alone. In PD and four-repeat tauopathy, prefrontal perfusion was related to ipsilateral nigrostriatal dopaminergic function. This dual-tracer frontostriatal relationship may be effectively used as a diagnostic tool for delineating PD from APS. © 2022 International Parkinson and Movement Disorder Society.

UI MeSH Term Description Entries
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D002560 Cerebrovascular Circulation The circulation of blood through the BLOOD VESSELS of the BRAIN. Brain Blood Flow,Regional Cerebral Blood Flow,Cerebral Blood Flow,Cerebral Circulation,Cerebral Perfusion Pressure,Circulation, Cerebrovascular,Blood Flow, Brain,Blood Flow, Cerebral,Brain Blood Flows,Cerebral Blood Flows,Cerebral Circulations,Cerebral Perfusion Pressures,Circulation, Cerebral,Flow, Brain Blood,Flow, Cerebral Blood,Perfusion Pressure, Cerebral,Pressure, Cerebral Perfusion
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015899 Tomography, Emission-Computed, Single-Photon A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image. CAT Scan, Single-Photon Emission,CT Scan, Single-Photon Emission,Radionuclide Tomography, Single-Photon Emission-Computed,SPECT,Single-Photon Emission-Computed Tomography,Tomography, Single-Photon, Emission-Computed,Single-Photon Emission CT Scan,Single-Photon Emission Computer-Assisted Tomography,Single-Photon Emission Computerized Tomography,CAT Scan, Single Photon Emission,CT Scan, Single Photon Emission,Emission-Computed Tomography, Single-Photon,Radionuclide Tomography, Single Photon Emission Computed,Single Photon Emission CT Scan,Single Photon Emission Computed Tomography,Single Photon Emission Computer Assisted Tomography,Single Photon Emission Computerized Tomography,Tomography, Single-Photon Emission-Computed
D050483 Dopamine Plasma Membrane Transport Proteins Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of dopaminergic neurons. They remove DOPAMINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS and are the target of DOPAMINE UPTAKE INHIBITORS. Dopamine Plasma Membrane Transporter Proteins,Neurotransmitter Transport Proteins, Dopamine-Specific,Neurotransmitter Transporters, Dopamine-Specific,DAT Dopamine Transporter,DAT Dopamine Transporter Proteins,Dopamine Carriers,Dopamine Transporter,Dopamine Transporter Proteins,Dopamine Uptake Complex,SLC6A3 Protein,Solute Carrier Family 6 (Neurotransmitter Transporter), Member 3 Protein,Carriers, Dopamine,Dopamine Transporter, DAT,Dopamine-Specific Neurotransmitter Transporters,Neurotransmitter Transport Proteins, Dopamine Specific,Neurotransmitter Transporters, Dopamine Specific,Protein, SLC6A3,Transporter Proteins, Dopamine,Transporter, DAT Dopamine,Transporter, Dopamine,Transporters, Dopamine-Specific Neurotransmitter
D020734 Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA. Autosomal Recessive Juvenile Parkinsonism,Familial Juvenile Parkinsonism,Parkinsonian Syndrome,Parkinsonism,Parkinsonism, Experimental,Parkinsonism, Juvenile,Ramsay Hunt Paralysis Syndrome,Autosomal Dominant Juvenile Parkinson Disease,Autosomal Dominant Juvenile Parkinsonism,Autosomal Dominant Parkinsonism,Autosomal Recessive Juvenile Parkinson Disease,Autosomal Recessive Parkinsonism,Chromosome 6-Linked Autosomal Recessive Parkinsonism,Experimental Parkinson Disease,Experimental Parkinsonism,Experimental Parkinsonism, MPTP-Induced,Familial Parkinson Disease, Autosomal Recessive,Juvenile Parkinson Disease,Juvenile Parkinson Disease, Autosomal Dominant,Juvenile Parkinson Disease, Autosomal Recessive,Juvenile Parkinsonism, Autosomal Dominant,Juvenile Parkinsonism, Autosomal Recessive,MPTP-Induced Experimental Parkinsonism,Parkinson Disease 2,Parkinson Disease 2, Autosomal Recessive Juvenile,Parkinson Disease Autosomal Recessive, Early Onset,Parkinson Disease, Autosomal Dominant. Juvenile,Parkinson Disease, Experimental,Parkinson Disease, Familial, Autosomal Recessive,Parkinson Disease, Juvenile,Parkinson Disease, Juvenile, Autosomal Dominant,Parkinson Disease, Juvenile, Autosomal Recessive,Parkinsonian Diseases,Parkinsonian Syndromes,Parkinsonism, Early Onset, with Diurnal Fluctuation,Parkinsonism, Early-Onset, With Diurnal Fluctuation,Parkinsonism, Juvenile, Autosomal Dominant,Parkinsonism, Juvenile, Autosomal Recessive,Chromosome 6 Linked Autosomal Recessive Parkinsonism,Diseases, Experimental Parkinson,Dominant Parkinsonism, Autosomal,Experimental Parkinson Diseases,Experimental Parkinsonism, MPTP Induced,Experimental Parkinsonisms,Juvenile Parkinsonism,Juvenile Parkinsonism, Familial,Juvenile Parkinsonisms,MPTP Induced Experimental Parkinsonism,Parkinson Diseases, Experimental,Parkinsonism, Autosomal Dominant,Parkinsonism, Autosomal Recessive,Parkinsonism, Familial Juvenile,Parkinsonism, MPTP-Induced Experimental,Parkinsonisms, Experimental,Parkinsonisms, Juvenile,Recessive Parkinsonism, Autosomal

Related Publications

Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
January 1968, Progress in brain research,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
January 1985, European neurology,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
September 1974, Revue medicale de Liege,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
August 1982, Archives of neurology,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
July 1993, Archives of neurology,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
August 2019, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
January 1986, Stroke,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
January 1989, The Journal of neuropsychiatry and clinical neurosciences,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
August 1991, British journal of clinical pharmacology,
Yoshikazu Nakano, and Shigeki Hirano, and Kazuho Kojima, and Honglinag Li, and Toru Sakurai, and Masahide Suzuki, and Hong Tai, and Shogo Furukawa, and Atsuhiko Sugiyama, and Yoshitaka Yamanaka, and Tatsuya Yamamoto, and Takashi Iimori, and Hajime Yokota, and Hiroki Mukai, and Takuro Horikoshi, and Takashi Uno, and Satoshi Kuwabara
September 1990, The British journal of psychiatry : the journal of mental science,
Copied contents to your clipboard!